The Precision Peptide Company Inc. Announces up to $2 Million LIFE Offering of Common Shares

About this update from Precision Peptide Company Inc

Vancouver, British Columbia--(Newsfile Corp. - June 11, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC") is pleased to announce that it intends to undertake a non-brokered private placement of a minimum of 3,000,000 and up to 4,000,000 common shares in the capital of the Company (the "Shares") at a price of $0.50 per Share for minimum gross proceeds of $1,500,000 and up to $2,000,000 (the "Offering"). The Offering is being completed pursuant to the listed issuer financing exemption under Part 5A of National Instrument 45-106 - Prospectus Exemptions, as amended by Coordinated Blanket Order 45-935 - Exemptions from Certain Conditions to the Listed Issuer Financing Exemption (the "LIFE Exemption") to purchasers resident in each of the Provinces of Canada, except Quebec. The Shares issued pursuant to the LIFE Exemption will not be subject to a hold period in accordance with applicable Canadian securities laws. There is an offering document related to the Offering available under the Company's profile at www.sedarplus.ca and on the Company's website at: www.precisionpeptidecompany.com. Prospective investors should read the offering document before making an investment decision. The Company intends to use the net proceeds from the Offering for general working capital purposes, to advance its business objectives, fund marketing initiatives and support the procurement of inventory and products. Closing of the Offering is expected to occur on or about June 25, 2026 and may occur in one or more tranches and completion of the Offering is subject to certain conditions including, but not limited to, the receipt of all necessary approvals. The Company may pay a finder's fee in connection with the Offering to eligible arm's length finders in accordance with the policies of the Canadian Securities Exchange. This press release shall not constitute an offer to sell or the solicitation of an offer to buy securities in the United States, nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, (the "1933 Act") or under any U.S. state securities laws, and may not...

View stock analysis, news, and events for Precision Peptide Company Inc